Home » Newsletters » BioWorld Asia

BioWorld Asia

March 26, 2003

View Archived Issues

British Biotech, RiboTargets Plan Merger Despite Reduced Valuation

LONDON - After two years of searching, British Biotech plc finally landed a merger partner, privately held RiboTargets Holdings plc, a structure-based drug discovery specialist that brings £19 million (US$30 million) to add to British Biotech's £32 million cash pile. (BioWorld International) Read More

Cellzome Lands EUR30M Financing For Programs In Drug Discovery

Study Elucidates Neural Networks Of The Spinal Cord In Mammals

Ingenium, Elan Collaborate To Develop Drugs To Manage Pain

Gamida-Cell, Teva Enter Deal To Develop Stem Cell Product

Biovitrum Moves Diabetes Drug Into Controlled Phase II Study

Basilea Planning Phase III Trial Of Lead Drug For Hand Dermatitis

Vernalis Results, Cash Shortfall Come As Surprise To Investors

Celltech's Acquisition Of Stake In OGS Puts Pressure On CAT

Genopole Now Boasts 42 Biotech Companies And 23 Laboratories

EU Leaders Continue To Express Support For Biotech - In Principle

Serono Demonstrates Efficacy Of Raptiva Over The Long Term

Other News To Note